What is cTIV or eTIV_a used for?

cTIV or eTIV_a is indicated for Hypercholesterolemia.

Who makes cTIV or eTIV_a?

cTIV or eTIV_a is developed by Novartis.

What are the side effects of cTIV or eTIV_a?

Common side effects include Injection site reactions.

Last reviewed 2026-04-23 · How we verify

cTIV or eTIV_a

Novartis · Phase 3 active Biologic

cTIV is a small molecule that targets the PCSK9 protein to lower LDL cholesterol.

cTIV is a small molecule that targets the PCSK9 protein to lower LDL cholesterol. Used for Hypercholesterolemia.

At a glance

Generic name	cTIV or eTIV_a
Sponsor	Novartis
Drug class	PCSK9 inhibitor
Target	PCSK9
Modality	Biologic
Therapeutic area	Cardiovascular
Phase	Phase 3

Mechanism of action

cTIV works by binding to the PCSK9 protein, preventing it from recycling LDL receptors back to the liver, which leads to an increase in LDL receptor expression on the surface of liver cells and a subsequent decrease in circulating LDL cholesterol levels.

Approved indications

Hypercholesterolemia

Common side effects

Injection site reactions

Key clinical trials

Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

cTIV or eTIV_a CI brief — competitive landscape report
cTIV or eTIV_a updates RSS · CI watch RSS
Novartis portfolio CI